NYSE:NVRO - Nevro Stock Price, Forecast & News

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro Corp (NYSE:NVRO) released its quarterly earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.85) by $0.27. The medical equipment provider had revenue of $100.16 million for the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative net margin of 25.94% and a negative return on equity of 46.35%. The business's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.37) earnings per share. View Nevro's Earnings History.

Nevro is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Nevro.

Nevro updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

12 brokers have issued twelve-month target prices for Nevro's shares. Their forecasts range from $65.00 to $144.00. On average, they expect Nevro's share price to reach $99.50 in the next twelve months. This suggests that the stock has a possible downside of 21.3%. View Analyst Price Targets for Nevro.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

Press coverage about NVRO stock has been trending extremely negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nevro earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Nevro.

Nevro saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 2,870,000 shares, a decrease of 8.0% from the December 15th total of 3,120,000 shares. Based on an average daily trading volume, of 410,600 shares, the days-to-cover ratio is presently 7.0 days. Approximately 9.7% of the company's stock are short sold. View Nevro's Current Options Chain.

Some companies that are related to Nevro include Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS) and Merit Medical Systems (MMSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Nevro's stock is owned by a number of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.01%), Nkcfo LLC (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Exchange Traded Concepts LLC (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, Nkcfo LLC, Exchange Traded Concepts LLC, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $126.43.

Nevro has a market capitalization of $3.92 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

The official website for Nevro is http://www.nevro.com/.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]